GSK OMB- OFATUMUMAB

Title: A phase 3 randomised study of Ofatumumab V’s Physicians choice in treatment of bulky Fludarabine refractory Chronic Lymphocytic Leukaemia (CLL)..

Population: Refractory to Fludarabine: Either no response to at least 2 cycles OR at least a Partial Response after 2 cycles lasting less than 6 months. Must have one Lymph Node >5cm.

Resource Links

http://clinicaltrials.gov/ct2/show/NCT01313689?term=OFATUMUMAB+CLL&rank=22

https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023066-52/IE

« Back